AssetMark Inc
ALNY icon

AssetMark Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

AssetMark Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.63M Buy
18,767
+4,437
+31% +$1.13M 0.01% 756
2026
Q2 		$4.31M Buy
14,330
+123
+0.9% +$37.1K 0.01% 770
2026
Q1 		$4.7M Sell
14,207
-1,826
-11% -$621K 0.01% 677
2025
Q4 		$6.38M Buy
16,033
+4,115
+35% +$1.82M 0.01% 608
2025
Q3 		$5.43M Buy
11,918
+375
+3% +$153K 0.01% 610
2025
Q2 		$3.76M Buy
11,543
+902
+8% +$250K 0.01% 649
2025
Q1 		$2.87M Buy
10,641
+608
+6% +$156K 0.01% 634
2024
Q4 		$2.36M Buy
10,033
+847
+9% +$223K 0.01% 671
2024
Q3 		$2.53M Buy
9,186
+700
+8% +$182K 0.01% 602
2024
Q2 		$2.06M Buy
8,486
+905
+12% +$143K 0.01% 610
2024
Q1 		$1.13M Buy
7,581
+668
+10% +$111K ﹤0.01% 699
2023
Q4 		$1.32M Buy
6,913
+1,135
+20% +$193K ﹤0.01% 612
2023
Q3 		$1.02M Buy
5,778
+934
+19% +$178K ﹤0.01% 610
2023
Q2 		$920K Buy
4,844
+475
+11% +$94.2K ﹤0.01% 629
2023
Q1 		$875K Buy
4,369
+306
+8% +$64.3K ﹤0.01% 624
2022
Q4 		$966K Buy
4,063
+1,271
+46% +$271K ﹤0.01% 588
2022
Q3 		$559K Buy
+2,792
New +$533K ﹤0.01% 635
2020
Q1 		– Sell
-96
Closed -$11K – 1349
2019
Q4 		$11K Hold
96
– – ﹤0.01% 1008
2019
Q3 		$8K Hold
96
– – ﹤0.01% 992
2019
Q2 		$7K Sell
96
-45
-32% -$3.45K ﹤0.01% 1006
2019
Q1 		$13K Hold
141
– – ﹤0.01% 944
2018
Q4 		$10K Buy
+141
New +$10.8K ﹤0.01% 1008
2018
Q1 		– Sell
-14
Closed -$2K – 1413
2017
Q4 		$2K Buy
14
+11
+367% +$1.38K ﹤0.01% 1415
2017
Q3 		$0 Buy
+3
New +$256 ﹤0.01% 1464

Other funds holding ALNY

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

AssetMark Inc's ALNY Position: Q3 2026 in Review

AssetMark Inc increased its Alnylam Pharmaceuticals (ALNY) stake by 31% in Q3 2026, buying an estimated $1.13M and bringing the position to 18,767 shares worth $4.63M. The position accounts for 0.01% of the portfolio, ranked #756.

AssetMark Inc first reported a position in ALNY in Q3 2017 and has held it in 24 quarters since. The position peaked at $6.38M in Q4 2025. 206 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • AssetMark Inc held 18,767 shares of Alnylam Pharmaceuticals worth $4.63M as of Q3 2026.
  • AssetMark Inc bought 4,437 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $1.13M.
  • Alnylam Pharmaceuticals made up 0.01% of AssetMark Inc's portfolio in Q3 2026, its #756 holding.
  • AssetMark Inc first reported a position in Alnylam Pharmaceuticals in Q3 2017 and has held it in 24 quarters since.
  • AssetMark Inc's Alnylam Pharmaceuticals position peaked at $6.38M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.